Oncurious NV
http://www.oncurious.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oncurious NV
Oxurion Eyes $12bn Opportunity After Restructuring
The Belgium-headquartered group is pulling the plug on its dry AMD research efforts and investments in cancer venture Oncurious to focus on two early-stage compounds that show promise for diabetic macular edema and other retinal diseases.
Company Information
- Industry
- Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice